The oral DPP-4 inhibitor linagliptin has been declared safe and effective in reducing glucose levels for up to 102 weeks, either as a stand-alone treatment or in combination with other selected oral anti-diabetic drugs, according to extended trials of individuals with type 2 diabetes in 32...
Orlando, 26 June 2010: Linagliptin, a dipeptidyl dipeptidase (DPP)-4 inhibitor being developed by Boehringer Ingelheim, achieves significant reductions in blood glucose in patients with type 2 diabetes both as monotherapy and in combination with other commonly used hypoglycaemic agents...